An international research team has identified a rare inherited mutation in the CDK12 gene that drives aggressive, metastatic prostate cancer in men as young as their early forties, a finding published this week in Cancer Discovery that reclassifies the gene as a hereditary risk factor, according to Dailybeirut.
The discovery shifts CDK12 from a gene thought to mutate only sporadically inside tumors to one that can be passed down through families, akin to BRCA1 and BRCA2.
Researchers at the University of British Columbia, BC Cancer, the Vancouver Coastal Health Research Institute, and the University of Washington, alongside collaborators in Australia, the Netherlands, Spain, and Belgium, analyzed genomic data from more than 4,500 patients with aggressive prostate cancer, according to La Tercera. They found five unrelated men carrying the germline mutation; all presented with metastatic disease between ages 44 and 62, La Tercera reported.
Until this work, the scientific consensus held that deleterious CDK12 alterations arose somatically—spontaneously within the tumor cells themselves—and were not heritable. To prove the mutations were germline drivers, the team hunted for a specific mutational signature, a genomic fingerprint left behind when the CDK12 protein loses its function in DNA repair.
Inherited CDK12 Mutation Signals Aggressive Prostate Cancer Risk
- A new hereditary risk flag: A rare mutation in the CDK12 gene can be inherited, not just acquired, and it signals a high risk for aggressive prostate cancer that spreads early.
- Actionable immediately: Current commercial genetic testing panels can detect this mutation; adding CDK12 to standard hereditary cancer panels is technically straightforward.
- Family cascade testing: Finding one carrier allows clinicians to test relatives, potentially catching cancer years before it becomes metastatic.
The Molecular Evidence: A Distinct Genomic Scar
Dr. Sofie Tolmeijer, the study’s lead author and a postdoctoral fellow in the Wyatt laboratory, explained that the tumors themselves provided the proof. “The tumors gave us a genetic signature that pointed directly to CDK12. This gave us compelling evidence that these inherited mutations were playing a direct role in causing their cancer,” she told La Tercera.
That signature—a specific pattern of tandem duplications and genomic instability—is the hallmark of homologous recombination deficiency (HRD). When CDK12 is inactivated, cells lose the ability to accurately repair double-strand DNA breaks. The presence of this HRD signature in the tumors of germline carriers confirmed the mutation was the engine of carcinogenesis, not a passenger event.
CDK12 Mutation Found in One in 1,000 Men Studied
The germline CDK12 mutation was identified in roughly 1 in 1,000 men with aggressive prostate cancer in the study cohort. While rare compared to BRCA2 alterations—which occur in 5% to 10% of hereditary cancer cases broadly—the researchers estimate the mutation could affect hundreds of families globally. Daily Beirut said that the 5% to 10% figure for all hereditary cancers underscores how much rarer the CDK12 variant is.
| Gene / Factor | Hereditary Context | Typical Clinical Presentation | Testing Availability |
|---|---|---|---|
| BRCA1/2 | Established high-penetrance hereditary cancer genes | Breast, ovarian, pancreatic, prostate; variable onset | Standard on all hereditary panels |
| CDK12 (New Finding) | Rare germline mutation; newly confirmed heritability | Aggressive, metastatic prostate cancer; diagnosis 44–62 yrs | Detectable via current NGS panels; recommended for inclusion |
| Somatic CDK12 | Acquired tumor mutation (non-heritable) | Metastatic castration-resistant prostate cancer (mCRPC) | Standard tumor profiling |
Clinical Implementation: From Bench to Bedside
A critical advantage of this discovery is the absence of a technological barrier. “One of the most promising aspects of this discovery is that we already have the technology needed to act on it,” Dr. Wyatt said. “Adding CDK12 to existing genetic tests is a relatively straightforward process, meaning this finding could move from the research lab to clinical practice much more quickly.”
This positions the finding for rapid integration into guidelines from bodies such as the National Comprehensive Cancer Network (NCCN) in the United States and the European Society for Medical Oncology (ESMO) in Europe. Currently, germline testing for prostate cancer typically focuses on BRCA1/2, ATM, CHEK2, and mismatch repair genes. The evidence presented in Cancer Discovery provides the molecular rationale to expand those panels.
Beyond the Prostate: A Potential Ovarian Cancer Link
The study also raises a hypothesis regarding ovarian cancer risk. Several of the identified prostate cancer patients had a family history of ovarian cancer.
Founded by provincial legislation in 1908, the University of British Columbia opened for classes in 1915 after absorbing McGill University College of British Columbia, which had provided the province’s first university-level instruction since 1906. The university now operates with an annual research budget of $893 million across two main campuses near Vancouver and Kelowna.
“This suggests CDK12 may be a shared hereditary risk factor for both prostate and ovarian cancers, similar to the BRCA paradigm,” Dr. Wyatt said in the study’s press materials. However, the authors emphasize that the ovarian cancer cohort was too small to establish penetrance or clinical guidelines. Further prospective studies are required to define the risk magnitude for female carriers.
Relatives of CDK12 Carriers Need Genetic Counseling
- Family cascade testing: First-degree relatives (parents, siblings, children) of a confirmed CDK12 carrier should be offered predictive genetic counseling and testing.
- Limitations: A negative CDK12 test does not eliminate hereditary risk; comprehensive panel testing remains standard. Positive results require interpretation by a certified genetic counselor to avoid unnecessary prophylactic surgery or anxiety.
- Immediate action: Any man with a known family mutation or urinary symptoms (hesitancy, frequency, blood in urine) should see a urologist for baseline PSA and imaging discussion, regardless of age.
References
- Tolmeijer S, et al. “Germline CDK12 mutations define a new hereditary prostate cancer syndrome.” Cancer Discovery.
- National Comprehensive Cancer Network (NCCN). Version 2.2024.
- Pritchard CC, et al.
- La Tercera. “Científicos descubren una nueva forma de cáncer de próstata hereditario: esto dice su investigación.” November 2026.
- Daily Beirut. “Una mutación en CDK12 vincula el cáncer de próstata hereditario.” November 13, 2026.